| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2022-03-07 02:52:00 UTC |
|---|
| HMDB ID | HMDB0015487 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Acenocoumarol |
|---|
| Description | Acenocoumarol, also known as mini-sintrom or acenokumarin, belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton. Acenocoumarol is a drug which is used for the treatment and prevention of thromboembolic diseases. more specifically, it is indicated for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. it is used for the treatment of deep vein thrombosis and myocardial infarction. A hydroxycoumarin that is warfarin in which the hydrogen at position 4 of the phenyl substituent is replaced by a nitro group. Acenocoumarol is an extremely weak basic (essentially neutral) compound (based on its pKa). In humans, acenocoumarol is involved in acenocoumarol action pathway. Acenocoumarol is a potentially toxic compound. |
|---|
| Structure | CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin | ChEBI | | 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin | ChEBI | | 3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin | ChEBI | | 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin | ChEBI | | 3-(alpha-p-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin | ChEBI | | 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one | ChEBI | | 4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one | ChEBI | | Acenocoumarin | ChEBI | | Acenocoumarolum | ChEBI | | Acenocumarol | ChEBI | | Acenocumarolo | ChEBI | | Acenokumarin | ChEBI | | Nicoumalone | ChEBI | | Nicumalon | ChEBI | | Nitrophenylacetylethyl-4-hydroxycoumarine | ChEBI | | Nitrovarfarian | ChEBI | | Nitrowarfarin | ChEBI | | Mini-sintrom | Kegg | | 3-(a-(4'-Nitrophenyl)-b-acetylethyl)-4-hydroxycoumarin | Generator | | 3-(Α-(4'-nitrophenyl)-β-acetylethyl)-4-hydroxycoumarin | Generator | | 3-(a-(p-Nitrophenol)-b-acetylethyl)-4-hydroxycoumarin | Generator | | 3-(Α-(p-nitrophenol)-β-acetylethyl)-4-hydroxycoumarin | Generator | | 3-(a-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin | Generator | | 3-(Α-acetonyl-4-nitrobenzyl)-4-hydroxycoumarin | Generator | | 3-(a-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin | Generator | | 3-(Α-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin | Generator | | 3-(a-p-Nitrophenyl-b-acetylethyl)-4-hydroxycoumarin | Generator | | 3-(Α-p-nitrophenyl-β-acetylethyl)-4-hydroxycoumarin | Generator | | Ciba-geigy brand OF acenocoumarol | HMDB | | Mini sintrom | HMDB | | Novartis brand OF acenocoumarol | HMDB | | Sinkumar | HMDB | | Syncoumar | HMDB | | Synthrom | HMDB | | Acenocoumarol alliance brand | HMDB | | Acenocoumarol novartis brand | HMDB | | Alliance brand OF acenocoumarol | HMDB | | Ciba geigy brand OF acenocoumarol | HMDB | | MiniSintrom | HMDB | | Syncumar | HMDB | | Acenocoumarol ciba-geigy brand | HMDB | | Sinthrome | HMDB | | Sintrom | HMDB |
|
|---|
| Chemical Formula | C19H15NO6 |
|---|
| Average Molecular Weight | 353.3255 |
|---|
| Monoisotopic Molecular Weight | 353.089937217 |
|---|
| IUPAC Name | 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one |
|---|
| Traditional Name | acenocumarolo |
|---|
| CAS Registry Number | 152-72-7 |
|---|
| SMILES | CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O |
|---|
| InChI Identifier | InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3 |
|---|
| InChI Key | VABCILAOYCMVPS-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Phenylpropanoids and polyketides |
|---|
| Class | Coumarins and derivatives |
|---|
| Sub Class | Hydroxycoumarins |
|---|
| Direct Parent | 4-hydroxycoumarins |
|---|
| Alternative Parents | |
|---|
| Substituents | - 4-hydroxycoumarin
- Benzopyran
- 1-benzopyran
- Nitrobenzene
- Nitroaromatic compound
- Pyranone
- Monocyclic benzene moiety
- Pyran
- Benzenoid
- Heteroaromatic compound
- Vinylogous acid
- Ketone
- Lactone
- C-nitro compound
- Organic nitro compound
- Oxacycle
- Organic oxoazanium
- Organoheterocyclic compound
- Allyl-type 1,3-dipolar organic compound
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Organic oxide
- Organic oxygen compound
- Organic nitrogen compound
- Carbonyl group
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 197 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.011 g/L | Not Available | | LogP | 1.98 | SANGSTER (1994) |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.49 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.6935 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.25 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 25.4 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Acenocoumarol,1TMS,isomer #1 | CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O | 3213.3 | Semi standard non polar | 33892256 | | Acenocoumarol,1TMS,isomer #2 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3315.9 | Semi standard non polar | 33892256 | | Acenocoumarol,1TMS,isomer #3 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3236.5 | Semi standard non polar | 33892256 | | Acenocoumarol,2TMS,isomer #1 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3311.8 | Semi standard non polar | 33892256 | | Acenocoumarol,2TMS,isomer #1 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3046.6 | Standard non polar | 33892256 | | Acenocoumarol,2TMS,isomer #1 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3728.1 | Standard polar | 33892256 | | Acenocoumarol,2TMS,isomer #2 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3230.0 | Semi standard non polar | 33892256 | | Acenocoumarol,2TMS,isomer #2 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 2921.6 | Standard non polar | 33892256 | | Acenocoumarol,2TMS,isomer #2 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C | 3729.3 | Standard polar | 33892256 | | Acenocoumarol,1TBDMS,isomer #1 | CC(=O)CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O | 3491.6 | Semi standard non polar | 33892256 | | Acenocoumarol,1TBDMS,isomer #2 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3611.0 | Semi standard non polar | 33892256 | | Acenocoumarol,1TBDMS,isomer #3 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3540.1 | Semi standard non polar | 33892256 | | Acenocoumarol,2TBDMS,isomer #1 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3829.8 | Semi standard non polar | 33892256 | | Acenocoumarol,2TBDMS,isomer #1 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3498.9 | Standard non polar | 33892256 | | Acenocoumarol,2TBDMS,isomer #1 | CC(=CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3827.7 | Standard polar | 33892256 | | Acenocoumarol,2TBDMS,isomer #2 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3740.5 | Semi standard non polar | 33892256 | | Acenocoumarol,2TBDMS,isomer #2 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3342.6 | Standard non polar | 33892256 | | Acenocoumarol,2TBDMS,isomer #2 | C=C(CC(C1=CC=C([N+](=O)[O-])C=C1)C1=C(O[Si](C)(C)C(C)(C)C)C2=CC=CC=C2OC1=O)O[Si](C)(C)C(C)(C)C | 3835.0 | Standard polar | 33892256 |
|
|---|
| General References | - Ufer M: Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46. [PubMed:16372822 ]
- Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J: The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006 Apr;133(2):183-7. [PubMed:16611310 ]
- Girard P, Nony P, Erhardtsen E, Delair S, Ffrench P, Dechavanne M, Boissel JP: Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost. 1998 Jul;80(1):109-13. [PubMed:9684795 ]
- Cesar JM, Garcia-Avello A, Navarro JL, Herraez MV: Aging and oral anticoagulant therapy using acenocoumarol. Blood Coagul Fibrinolysis. 2004 Oct;15(8):673-6. [PubMed:15613922 ]
- Lengyel M: [Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?]. Orv Hetil. 2004 Dec 26;145(52):2619-21. [PubMed:15724697 ]
|
|---|